Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management
Shots:
- Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world
- Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific conditions, while Roche will manage commercial manufacturing & supply
- As per the deal, Zealand will get $1.65B upfront ($1.4B at closing + $250M over 2yrs.), ~$1.2B upon start of P-III trials, & ~$2.4B in sales-based milestones, plus tiered royalties, while Roche will get $350M for CT-388 as the 1st combination. Companies will share 50/50 US & EU profits/losses for monotx. & combo products
Ref: Roche | Image: Roche & Zealand Pharma
Related News:- Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
